[go: up one dir, main page]

MX2019012884A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2019012884A
MX2019012884A MX2019012884A MX2019012884A MX2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A
Authority
MX
Mexico
Prior art keywords
combination
proliferative disease
treatment
subject
present
Prior art date
Application number
MX2019012884A
Other languages
English (en)
Other versions
MX393855B (es
Inventor
Cooke Vesselina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019012884A publication Critical patent/MX2019012884A/es
Publication of MX393855B publication Critical patent/MX393855B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (a) un inhibidor de Raf conforme lo definido en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de MEK, particularmente trametinib, particularmente para usarse en el tratamiento de una enfermedad proliferativa. La presente invención además se refiere a usos de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a métodos de tratamiento de una enfermedad proliferativa en un sujeto que lo necesite que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente efectiva de dicha combinación; al uso de tal combinación para el tratamiento de una enfermedad proliferativa; a composiciones farmacéuticas que comprenden tal combinación y a envases comerciales para las mismas.
MX2019012884A 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib MX393855B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en) 2017-05-02 2018-04-30 Combination therapy

Publications (2)

Publication Number Publication Date
MX2019012884A true MX2019012884A (es) 2020-01-14
MX393855B MX393855B (es) 2025-03-21

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012884A MX393855B (es) 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib

Country Status (17)

Country Link
US (2) US11266653B2 (es)
EP (2) EP4272740A1 (es)
JP (3) JP7309614B2 (es)
KR (2) KR102641827B1 (es)
CN (1) CN110494166B (es)
AU (1) AU2018262891B2 (es)
CA (1) CA3057969A1 (es)
CL (1) CL2019003091A1 (es)
DK (1) DK3618875T3 (es)
ES (1) ES2952265T3 (es)
FI (1) FI3618875T3 (es)
IL (2) IL311471A (es)
MX (1) MX393855B (es)
PL (1) PL3618875T3 (es)
PT (1) PT3618875T (es)
TW (1) TWI798218B (es)
WO (1) WO2018203219A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
JP7309614B2 (ja) * 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
EP3665302A4 (en) * 2017-08-11 2021-04-28 Curematch, Inc. COMBINED MEDICINAL PRODUCTS AGAINST MULTIPLE MUTATIONS IN CANCER
KR20210105388A (ko) * 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
CN113795490A (zh) 2019-05-13 2021-12-14 诺华股份有限公司 N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症
EP4106756A1 (en) * 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
EP4115907A4 (en) * 2020-02-27 2024-07-03 National University Corporation Hokkaido University METHODS OF SCREENING ANTI-CANCER AGENTS AND COMBINATION MEDICINAL AGENTS OF KINASE INHIBITORS FOR THE TREATMENT OF PANCREAS CANCER
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
WO2022043955A1 (en) * 2020-08-31 2022-03-03 Novartis Ag Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
JPWO2023145530A1 (es) * 2022-01-27 2023-08-03
JP2025507955A (ja) 2022-03-02 2025-03-21 ノバルティス アーゲー 癌の治療のための精密療法
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024088273A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗kras突变相关疾病的用途
WO2024088275A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗耐药性肿瘤的用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2001500482A (ja) 1996-08-27 2001-01-16 ノバルティス アクチェンゲゼルシャフト 除草性ｓ置換１，２，４，６―チアトリアジン類
ES2384551T3 (es) 1997-03-05 2012-07-06 Sugen, Inc. Formulaciones para agentes farmacéuticos hidrófobos
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6465493B1 (en) 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
AU7031500A (en) 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
EP1233769B1 (en) 1999-11-22 2007-12-26 SmithKline Beecham plc Imidazole derivatives
ES2222336T3 (es) 2000-01-18 2005-02-01 Vertex Pharma Inhibidores de girasas y sus usos.
AU2001232809A1 (en) 2000-01-18 2001-07-31 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US7495018B2 (en) 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DE60137426D1 (de) 2000-06-12 2009-03-05 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
KR100773621B1 (ko) 2000-07-19 2007-11-05 워너-램버트 캄파니 엘엘씨 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
AU2002227269A1 (en) 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1343779B1 (en) 2000-11-20 2007-06-27 Smithkline Beecham Corporation Novel compounds
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2002064136A2 (en) 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2003082272A1 (en) 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
HRP20050250A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor
DE60328028D1 (de) 2002-09-18 2009-07-30 Pfizer Prod Inc Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
EP1673343A4 (en) 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CA2542653A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
JP4853284B2 (ja) 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
EP1761528B1 (en) 2004-06-11 2008-01-09 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
US8217037B2 (en) 2006-04-07 2012-07-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
CA2659604C (en) 2006-08-08 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
SI2170848T1 (sl) 2007-06-27 2015-01-30 Astrazeneca Ab Derivati pirazinona in njihova uporaba pri zdravljenju bolezni pljuč
US7968536B2 (en) 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
US20100240657A1 (en) 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
JP2010533159A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RU2474580C2 (ru) 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
TW200916458A (en) 2007-09-05 2009-04-16 Astrazeneca Ab Heterocyclic compounds and methods of use thereof
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
CN102015686B (zh) 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009257372A1 (en) 2008-06-11 2009-12-17 Irm Llc Compounds and compositions useful for the treatment of malaria
EA019722B1 (ru) 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
PE20110419A1 (es) 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SI3354650T1 (sl) 2008-12-19 2022-06-30 Vertex Pharmaceuticals Incorporated Spojine, uporabne kot zaviralci ATR kinaze
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2010291206A1 (en) 2009-09-04 2012-02-23 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
WO2011059610A1 (en) 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
AU2010339271B2 (en) 2009-12-28 2015-09-03 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-oxadiazole-2-carboxamide compound
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
JP5903433B2 (ja) 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CN103517710B (zh) 2011-02-07 2017-05-31 普莱希科公司 用于激酶调节的化合物
EP2686317A4 (en) 2011-03-17 2014-08-20 Selexagen Therapeutics Inc RAF KINASE INHIBITORS
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
PH12014500372A1 (en) 2011-09-01 2014-04-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
WO2013164769A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
MX2014013373A (es) 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
WO2014008214A1 (en) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Biaryl-containing compounds as inverse agonists of ror-gamma receptors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
PE20191655A1 (es) 2012-08-07 2019-11-07 Novartis Ag Combinaciones farmaceuticas
ES2900825T3 (es) * 2012-09-04 2022-03-18 Novartis Ag Método de tratamiento adyuvante para el cáncer
NZ706857A (en) 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
EP3063143B1 (en) 2013-11-01 2018-05-16 Novartis AG Aminoheteroaryl benzamides as kinase inhibitors
RU2722784C2 (ru) 2013-12-20 2020-06-03 Байомед Вэлли Дискавериз, Инк. Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
CN107074828B (zh) 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
CN107001329B (zh) 2014-09-12 2020-09-01 诺华股份有限公司 作为激酶抑制剂的化合物和组合物
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
CN113307805A (zh) 2015-04-15 2021-08-27 百济神州有限公司 B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
JP6892431B2 (ja) 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
JP2018528952A (ja) 2015-08-28 2018-10-04 ノバルティス アーゲー Ｐｉ３ｋ阻害剤のアルペリシブおよびｃｄｋ４／６阻害剤のリボシクリブを含む医薬組合せ、ならびにがんの治療／予防におけるその使用
WO2017037587A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
PT3463345T (pt) 2016-06-03 2023-01-06 Array Biopharma Inc Combinações farmacêuticas
EP3468595A1 (en) 2016-06-10 2019-04-17 Novartis AG Therapeutic uses of a c-raf inhibitor
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018107146A1 (en) 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
JP7309614B2 (ja) * 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
CN116036278B (zh) 2017-05-16 2024-12-17 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
WO2020046966A1 (en) 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
KR20210105388A (ko) 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
CN113795490A (zh) 2019-05-13 2021-12-14 诺华股份有限公司 N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症
EP4106756A1 (en) 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
CN115551509A (zh) 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合
WO2022043955A1 (en) 2020-08-31 2022-03-03 Novartis Ag Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma

Also Published As

Publication number Publication date
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
US11266653B2 (en) 2022-03-08
JP7309614B2 (ja) 2023-07-18
BR112019022511A2 (pt) 2020-05-12
TWI798218B (zh) 2023-04-11
CN110494166A (zh) 2019-11-22
CL2019003091A1 (es) 2020-02-07
JP7520189B2 (ja) 2024-07-22
AU2018262891A1 (en) 2019-10-17
EP3618875B1 (en) 2023-04-05
FI3618875T3 (fi) 2023-07-04
KR20190141164A (ko) 2019-12-23
ES2952265T3 (es) 2023-10-30
MX393855B (es) 2025-03-21
JP2020518568A (ja) 2020-06-25
IL270224A (es) 2019-12-31
CN110494166B (zh) 2022-11-08
IL270224B1 (en) 2024-04-01
JP2023145467A (ja) 2023-10-11
WO2018203219A1 (en) 2018-11-08
US20200246346A1 (en) 2020-08-06
RU2019134757A (ru) 2021-06-02
JP2024160223A (ja) 2024-11-13
DK3618875T3 (da) 2023-07-10
RU2019134757A3 (es) 2021-08-17
CA3057969A1 (en) 2018-11-08
US12036227B2 (en) 2024-07-16
AU2018262891B2 (en) 2021-04-01
EP4272740A1 (en) 2023-11-08
PT3618875T (pt) 2023-08-07
IL311471A (en) 2024-05-01
KR102641827B1 (ko) 2024-03-04
PL3618875T3 (pl) 2023-10-23
US20220143036A1 (en) 2022-05-12
EP3618875A1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
MX2019009443A (es) Metodos para tratar la influenza.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
AR108792A1 (es) Composiciones que comprenden timolol